China Sky One Medical, Inc. Interviewed in The China Perspective

HARBIN, China, Dec. 5 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical took part in an insightful interview in today's issue of The China Perspective.

As a well-known pharmaceutical company in China, China Sky One was honored to receive an interview from The China Perspective, a leading source of China business news, research and analysis that provides insight into the trends, companies and industries that are shaping the Chinese economy. During the interview, Mr. Yan-Qing Liu spoke about the Company's recent acquisitions, its R&D capability and the impact of global financial crisis on pharmaceutical producers. For more information, please visit The China Perspective's website ( http://www.thechinaperspective.com ).

"This is an exciting time in the evolution of the pharmaceutical industry in China, and China Sky One is well positioned to offer insight as a leading drug manufacturer and distributor in China," commented Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We are thrilled to work with The China Perspective and to share our reflections about the global economic crisis and our expertise in the Chinese pharmaceutical market with the investment community."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR''), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Company Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yubo Hao, CFO

Tel: +86-451-5399-4069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Web site: http://www.ccgirasia.com